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Abstract
In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction (HFrEF), therapeutic efforts in 
the past have failed to improve outcomes in heart failure with preserved ejection fraction (HFpEF). Moreover, to this day, 
diagnosis of HFpEF remains controversial. However, there is growing appreciation that HFpEF represents a heterogeneous 
syndrome with various phenotypes and comorbidities which are hardly to differentiate solely by LVEF and might benefit 
from individually tailored approaches. These hypotheses are supported by the recently presented PARAGON-HF trial. 
Although treatment with LCZ696 did not result in a significantly lower rate of total hospitalizations for heart failure and 
death from cardiovascular causes among HFpEF patients, subanalyses suggest beneficial effects in female patients and those 
with an LVEF between 45 and 57%. In the future, prospective randomized trials should focus on dedicated, well-defined 
subgroups based on various information such as clinical characteristics, biomarker levels, and imaging modalities. These 
could clarify the role of LCZ696 in selected individuals. Furthermore, sodium-glucose cotransporter-2 inhibitors have just 
proven efficient in HFrEF patients and are currently also studied in large prospective clinical trials enrolling HFpEF patients. 
In addition, several novel disease-modifying drugs that pursue different strategies such as targeting cardiac inflammation 
and fibrosis have delivered preliminary optimistic results and are subject of further research. Moreover, innovative device 
therapies may enhance management of HFpEF, but need prospective adequately powered clinical trials to confirm safety and 
efficacy regarding clinical outcomes. This review highlights the past, present, and future therapeutic approaches in HFpEF.
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Introduction
Heart failure (HF) poses a growing burden for health 
systems worldwide as incidence and prevalence is rising 
annually. Typically, the term HF was applied to patients 
with reduced ejection fraction only, until the first reports 
on patients suffering from symptoms of HF despite hav-
ing normal left-ventricular ejection fraction (LVEF) and 
small hearts emerged [1–3]. Initially, the condition was 
referred to as “diastolic heart failure” according to the 
different appearance compared to “systolic heart failure”. 
However, this has led to discussions among the scientific 
community, since a clear differentiation between systolic 
and diastolic dysfunction is rather hypothetical than physi-
ological [4]. It was even shown that severity of diastolic 
dysfunction may be greater in patients with impairment 
of systolic function than in those without [5] and that 
systolic dysfunction can also be detected in patients with 
preserved ejection fraction [6]. Therefore, the European 
Society of Cardiology (ESC) focused on objective find-
ings and proposed the term “heart failure with preserved 
ejection fraction” (HFpEF). In the latest 2016 guidelines, 
HF is differentiated in three different forms depending 
on LVEF: HFpEF (LVEF ≥ 50%), HFrEF (“heart fail-
ure with reduced ejection fraction”, LVEF < 40%), and 
HFmEF (“heart failure with mid-range ejection fraction”, 
LVEF > ≥ 40 and < 50%) [7]. In contrast to the latest 
advances in therapy of HFrEF, HFpEF remains a chal-
lenge, in which many established HF drugs have failed to 
improve prognosis. This review highlights the main epide-
miological and pathophysiological aspects in HFpEF and 
discusses dilemmas in management of HFpEF as well as 
promising therapeutic options for the future.
Dilemma in diagnosing HFpEF
HFpEF mostly affects older patients, predominantly 
females. Depending on various factors (e.g., definition and 
time of publication), the proportion of HFpEF among HF 
patients ranges from 22 to 73% [7]. Patients with HFpEF 
are a heterogeneous group with numerous underlying 
aetiologies and pathophysiological abnormalities [7]. 
Thus, diagnosis of HFpEF can be challenging, as it rather 
describes a clinical syndrome than a single clinical diag-
nosis [8]. Also, there have been debates whether the defi-
nition of HFpEF should be based solely on LVEF, since 
LVEF-based HF subgroups may exhibit significantly over-
lapping phenotypes [9]. This issue has resulted in proposi-
tion of diagnostic algorithms which take various diagnos-
tic measures such as clinical characteristics, laboratory 
and echocardiographic findings, as well as sophisticated 
imaging modalities and invasive haemodynamic meas-
urements into account. For instance, a composite HFpEF 
score determined by presence of atrial fibrillation, obe-
sity, age > 60  years, treatment with ≥ 2 antihyperten-
sives, echocardiographic E/e′ ratio > 9, and echocardio-
graphic pulmonary artery systolic pressure > 35 mmHg 
has been shown to substantially identify patients at high 
risk of HFpEF that should undergo further evaluation 
[10]. According to the updated consensus recommenda-
tion by the Heart Failure Association (HFA) of the ESC 
[8], a step-wise diagnostic process should be applied in 
patients with suspected HFpEF. After an initial work-up 
based on clinical parameters and non-invasive tests (e.g. 
ECG, echocardiography, blood tests), the authors sug-
gest a risk stratification by using the ‘HFA-PEFF’ score 
in selected patients. In this score, patients are stratified 
in three different groups (low risk, intermediate risk, and 
high risk) according to echocardiographic parameters and 
biomarker levels. While patients identified as high risk 
should be diagnosed with HFpEF, patients at intermedi-
ate risk should undergo echo stress tests or if inconclu-
sive, invasive haemodynamic measurements, to establish 
the diagnosis of HFpEF. Finally, the authors recommend 
an aetiological work-up which includes ergometry, blood 
tests, genetic testing, imaging modalities (particularly 
cardiac magnetic resonance imaging), and, in rare cases, 
myocardial biopsy. This suggested exclusion of specific 
causes in the etiology of HFpEF, for example primary 
cardiomyopathies and storage diseases such as M. Fabry 
and amyloidosis, as well as pericardial diseases such as 
constrictive pericarditis, may be crucial for an individually 
tailored specific treatment of the HFpEF syndrome. For 
instance, initiation of tafamidis in transthyretin amyloid 
cardiomyopathy is of great importance, as these patients 
suffer from a poor prognosis [11]. If untreated, the median 
survival time of patients with a wild-type transthyretin 
amyloidosis is 3.6 years after diagnosis and 2.5 years with 
a hereditary transthyretin amyloidosis [12, 13]. The ben-
zoxazole derivative tafamidis prevents amyloidogenesis 
by binding to the thyroxine-binding sites of transthyretin. 
In the recent Transthyretin Amyloidosis Cardiomyopathy 
Clinical Trial (ATTR-ACT) including 441 patients with 
transthyretin amyloid cardiomyopathy, therapy with tafa-
midis led to a significant reduction in all-cause mortality 
and rate of CV hospitalizations compared to placebo [14].




Currently, the precise pathophysiological processes in 
HFpEF are incompletely resolved, since animal models are 
sparse. This is due to a high prevalence of comorbidities 
in HFpEF patients, which is difficult to be translated into 
animal models, which are typically younger and less 
comorbid [4]. However, there is consensus that HFpEF 
is associated with systemic inflammation [15], which is 
triggered by the cumulative expression of various risk fac-
tors and comorbidities (Fig. 1). If no specific disease is 
the cause, the most common risk factors/comorbidities of 
Fig. 1  Current model on pathophysiology and management of 
comorbidities and risk factors in HFpEF. Cumulative expression of 
the shown comorbidities and risk factors can cause systemic inflam-
mation which can then lead to development of HFpEF [2]. ACEI 
angiotensin-converting enzyme inhibitor, ARB angiotensin recep-
tor blocker, CCB calcium channel blocker, MRA mineralocorticoid 
receptor antagonist, PDE5 hosphodiesterase-5, sCG soluble guanylate 
cyclase, SGLT2 sodium-glucose cotransporter-2. Figure modified 
according to Tschöpe et al. [4] and Lam et al. [9]
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HFpEF are age, female gender, renal impairment, diabetes, 
hypertension, as well as obesity and deconditioning [16]. 
Typically, in contrast to HFrEF patients, patients suffering 
from HFpEF are older, have a higher average body mass 
index, are more likely to be female, and exhibit a lower 
prevalence of ischemic heart disease [17]. Activation of 
the endothelium through the systemic inflammatory state 
eventually causes oxidative stress [18]. As a consequence, 
reactive oxygen species (ROS) directly react with nitric 
oxide (NO) and reduce its bioavailability. In addition, ROS 
may cause eNOS uncoupling which leads to production 
of highly reactive superoxide  (O2−) instead of NO. These 
processes result in a vasoconstricting, pro-inflammatory, 
and pro-thrombotic state of endothelial dysfunction [19]. 
Furthermore, alterations of both the myocytic and non-
myocytic compartment can increase diastolic stiffness 
and may contribute to development of HFpEF [20, 21]. 
For instance, reduction of NO bioavailability by oxida-
tive stress and inflammatory cytokines downregulates the 
nitrogen monoxide–cyclic guanosine monophosphate–pro-
tein kinase G (NO–cGMP–PKG) pathway, and, therefore, 
decreases PKG activity. PKG plays an essential role in 
regulating phosphorylation, isoform switching, and oxida-
tive modifications of the cytoskeletal protein titin, which 
mainly determines cardiomyocyte stiffness [22]. Besides 
cardiomyocyte stiffness, changes in the composition and 
structure of the non-myocytic compartment contribute to 
diastolic stiffness [19]. Endothelial dysfunction is asso-
ciated with adherence and infiltration of monocytes and 
stimulation of integrated macrophages. By secretion of 
pro-fibrotic substances, in particular transforming growth 
factor β (TGF-β) [23], these cells promote myofibroblast 
differentiation and eventually collagen secretion, leading 
to extracellular fibrosis [24, 25]. In addition, galectin-3, 
a lectin-binding galactoside, has been suggested to be 
another major mediator of myocardial fibrosis in HFpEF, 
which enhances collagen secretion by binding to myofibro-
blasts and may be in part responsible for the conferral of 
the detrimental effects of aldosterone [26, 27]. Moreover, 
myocardial fibrosis in HFpEF can result from hyperten-
sion, aging, metabolic triggers, and infrequently repara-
tive processes [28]. Finally, cardiometabolic functional 
abnormalities, e.g., abnormal mitochondrial structure and 
function, change in substrate utilization and intracellular 
calcium overload, are thought to be another important 
pathomechanism in HFpEF, although these assumptions 
are primarily derived from studies in HFrEF [29].
Treatment of HFpEF
Focus on comorbidities
Clinical findings suggest that prognosis in patients with 
HFpEF is highly influenced by comorbidities [30–32]. 
This concept is addressed in the OPTIMIZE-HFpEF trial 
(NCT02425371). Thus, adequate treatment of comor-
bidities in HFpEF might be of crucial importance and 
patients should be regularly screened for these conditions 
[33] (Fig. 1). For instance, obesity and deconditioning are 
common risk factors in HFpEF. In a sub-analysis of the 
I-PRESERVE trial, 71% of all 4109 patients had a body 
mass index ≥ 26.5 kg/m2 and 21% had a BMI between 23.5 
and 26.4% kg/m2 [34]. Moreover, the risk for the primary 
endpoint (death from any cause or hospitalization for a 
CV cause, that is, HF, myocardial infarction, unstable 
angina, arrhythmia, or stroke) was increased in patients 
with BMI < 23.5 kg/m2 and in those with BMI ≥ 35 kg/
m2. Both physical activity (PA) and caloric restriction 
are important non-pharmacological approaches to reduce 
obesity and deconditioning and have shown to be associ-
ated with prognostic effects. In a post hoc analysis of the 
TOPCAT trial, risk of HF hospitalization and mortality 
was lower in physically high-active HFpEF patients than 
in intermediate-active and poorly active patients [35]. In 
the prospective Ex-DHF pilot trial, supervised exercise 
training (ET) improved exercise capacity and QOL and 
led to atrial reverse remodeling and reduction of diastolic 
dysfunction in HFpEF patients [36]. The ongoing Ex-DHF 
trial aims to evaluate long-term effects of supervised ET 
on a total of 320 patients [37]. Furthermore, prescrip-
tion of a 20-week hypocaloric diet was associated with 
an increased peak VO2 in a cohort of 100 obese HFpEF 
patients, most of which were female (81%). In addition, 
the effects were even greater when patients also had to 
join supervised exercise sessions three times a week, sug-
gesting the combination of PA and diet to provide addi-
tive effects [38]. Another important comorbidity in HF 
patients is anemia due to iron deficiency [7]. In a small 
study with 190 symptomatic HFpEF patients, iron defi-
ciency was present in 58.4% of all patients, while only 54 
patients showed a corresponding anemia [39]. Interest-
ingly, iron deficiency was significantly more prevalent in 
patients with severe diastolic dysfunction, and was asso-
ciated with reduced exercise capacity and quality of life 
(QOL). Intravenously administered iron improves symp-
toms and QOL in patients with HFrEF [40]. Enhancing 
mitochondrial energy supply by iron supplementation has 
been discussed as one underlying mechanism, but whether 
this affects cardiac and/or skeletal muscles is currently 
unclear [41, 42]. Two current randomized-controlled 
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trials (RCTs) (FAIR-HFpEF, PREFER-HF) focus on the 
effects of intravenously administered iron primarily on 
functional capacity in terms of six-minute walking dis-
tance (6MWD) as well as morbidity and mortality in 
HFpEF patients (NCT03074591, NCT03833336). Moreo-
ver, hypertension can cause recurring hospitalizations in 
HFpEF [43] and needs to be treated in accordance to the 
current hypertension guidelines [44]. Myocardial ischemia 
has also been frequently reported in HFpEF patients, con-
tributing to greater deterioration in ventricular function 
and increased mortality [45]. Therefore, special emphasis 
should also be placed on adequate diagnostic measures 
and revascularization strategies. Additionally, atrial fibril-
lation (AF), the most common arrhythmia, often coexists 
with HFpEF [46]. According to a post hoc analysis of the 
TOPCAT trial, detection of AF represents an independ-
ent risk factor of adverse cardiovascular (CV) outcome 
(composite endpoint of CV mortality, aborted cardiac 
arrest, or HF hospitalization) [47]. While catheter abla-
tion of AF leads to increased survival rates compared to 
antiarrhythmic drug therapy in HFrEF [48, 49], it is cur-
rently unclear if these effects equally account for HFpEF 
patients [50]. In a small retrospective analysis, effects of 
catheter ablation on symptom burden, NYHA functional 
class, in-hospital adverse event rate, and freedom from 
recurrent atrial arrhythmia at 12 months were similar in 
97 HFrEF (LVEF < 50%) and 133 HFpEF (LVEF ≥ 50%) 
patients [51]. However, adequately powered, randomized 
trials are necessary, to assess the value of AF ablation in 
the collective of HFpEF patients.
Dilemmas in past HFpEF trials
In past trials, there have been significant differences regard-
ing the definition of HFpEF. In contrast to the ESC definition 
(LVEF ≥ 50%), major clinical trials such as the TOPCAT 
trial [52] or the recent PARAGON-trial [53] have included 
patients with an LVEF ≥ 45%. However, as mentioned, there 
are increasing concerns about defining HFpEF by LVEF 
only [9]. Furthermore, it is essential to acknowledge HFpEF 
as a heterogeneous syndrome most likely comprising vari-
ous pathophysiological phenotypes which might need to be 
treated differently. Therefore, future clinical trials should 
focus on dedicated, well-defined patient cohorts which 
should not be solely based on LVEF.
Conventional HF drugs in HFpEF
ACE inhibitors and AT1 antagonists
Stimulation of AT1 receptors induces myocardial hypertro-
phy and fibrosis which can then lead to HF [54]. ACE inhib-
itors and angiotensin II receptor blockers (ARBs), which 
target the renin–angiotensin–aldosterone system (RAAS) 
pathway and inhibit the activation of AT1 receptors, reduce 
morbidity and mortality in patients with HFrEF [55–57]. In 
patients with HFpEF, however, they have failed to improve 
clinical outcomes. In the I-PRESERVE trial, irbesartan did 
not reduce hospitalization rates for CV causes or all-cause 
mortality in patients with HF and LVEF of at least 45% [58]. 
In the CHARM-PRESERVED study, candesartan reduced 
HF hospitalizations, but not CV death rates [59]. Perindopril 
has been shown to improve symptoms and exercise capac-
ity but not morbidity or mortality in 850 elderly patients 
with a mean age of 76 years (PEP-CHF) [60]. The VALIDD 
study compared effects of valsartan to other antihyperten-
sive agents in patients with evidence of diastolic dysfunction 
and hypertension [61]. In both groups, diastolic function 
improved after reduction of blood pressure, regardless of 
the antihypertensive treatment.
Mineralocorticoid receptor antagonists
Mineralocorticoid receptor antagonists (MRAs) prevent 
the maladaptive effects of aldosterone. Aldosterone medi-
ates myocardial fibrosis [62], contributing to myocardial 
stiffness and filling abnormalities. The ALDO-DHF trial 
proved that spironolactone had a positive impact on dias-
tolic function by reducing the E/e′-ratio and decreased left-
ventricular (LV) hypertrophy and NT-proBNP levels [63]. 
Surprisingly, HF symptoms, exercise tolerance, and QOL 
have not been significantly affected by spironolactone. In 
the international, multicenter TOPCAT trial, spironolac-
tone failed to significantly improve CV outcomes in 3445 
HFpEF patients (LVEF ≥ 45%) [52]. However, these find-
ings might have been biased by regional differences. As 
compared to patients enrolled in the US, Canada, Brazil, 
and Argentina (the Americas), patients enrolled in Rus-
sia and Georgia exhibited markedly lower clinical event 
rates [64] and their concentrations of canrenone, an active 
metabolite of spironolactone, were much more likely to be 
undetectable, suggesting higher rates of patients’ incom-
pliance [65]. These aspects might explain why spironol-
actone was able to reduce risk of CV death and HF hospi-
talization in the American population, while this did not 
account for patients from Russia and Georgia [64]. Fur-
thermore, treatment effects of spironolactone were influ-
enced by LVEF and have reached significance at the lower 
end of the ejection fraction spectrum [66]. As a result, 
MRAs can now be considered to decrease hospitalizations 
in appropriately selected patients with HFpEF, according 
to the updated ACC/AHA/HFSA guidelines [67]. Criti-
cally, it needs to be outlined that the regional interaction 
analyses of the TOPCAT trial were post hoc, which can, 
therefore, only serve as hypothesis generating. In addi-
tion, the p value for the treatment-by-region-interaction 
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was not significant (p = 0.12) [64]. Moreover, when mak-
ing recommendations about HF therapy based on regional 
interaction analyses, this should be equally applied to all 
HF drugs. For instance, beta-blockers have not shown any 
beneficial effects in the US population [68, 69], but are 
still recommended as an essential part of HF therapy in 
the USA. Furthermore, the potential mistakes in Russia 
and Georgia implied by the mentioned post hoc analy-
ses were only possible because of the trial organization 
which wanted to save money by including Russians and 
Georgians.
In the future, new studies such as the German pro-
spective SPIRIT-HF trial (2017-000697-11) and the 
large registry-randomized clinical trial SPIRRIT-HF 
(NCT02901184) will reevaluate therapy with spironolac-
tone in HFpEF patients. In SPIRIT-HF, particular empha-
sis will lie on patient characterization and selection. Novel 
MRAs, such as nonsteroidal aldosterone antagonists, will 
also be evaluated [70, 71].
Beta‑blockers
High heart rate (HR) predicts poor outcome in patients with 
HFpEF and sinus rhythm, but does not apply for those in 
atrial fibrillation, as shown in a post hoc analysis of the 
I-PRESERVE trial [72]. These findings were supported by 
a sub-analysis of the CHART-2 study, in which elevated 
HR was associated with a higher CV mortality in HFpEF 
patients [73]. The MAGICC registry confirmed the prog-
nostic association of HR in sinus rhythm, but not in atrial 
fibrillation in 2285 HFrEF and 974 HFpEF patients [74]. 
Thus, several studies investigated whether beta-blockers 
induce positive prognostic effects in patients with HFpEF 
by helping to reduce HR. In a pre-specified sub-analysis of 
the SENIORS trial, no significant differences were observed 
regarding the prognostic impact of nebivolol, a β1-selective 
beta-blocker, in patients with impaired and preserved LV 
function (separation in this trial was LVEF > 35%) [75]. In 
the ELANDD study, 6 month treatment with nebivolol led to 
a reduction in HR, while it had no effect on exercise capacity 
in terms of 6MWTD and peak oxygen consumption (VO2) in 
116 HFpEF patients [76]. A large meta-analysis on the prog-
nostic effects of beta-blockers in HFpEF showed a reduc-
tion in mortality by 21%, but results were mainly influenced 
by findings from observational cohort studies [77]. In the 
pooled analysis of RCTs only, use of beta-blockers was asso-
ciated with a reduced risk of mortality but without reach-
ing statistical significance. The OPTIMIZE-HF registry, on 
the other hand, did not find a relevant prognostic effect of 
beta-blocker treatment in patients with HFpEF [17]. How-
ever, both the mentioned meta-analysis [77] and the OPTI-
MIZE-HF registry [17] did not assess potential differences 
in therapeutic efficacy between the different sub-classes of 
beta-blockers. Perhaps, beneficial effects may be present in 
selected sub-classes of beta-blockers which would need to 
be evaluated in further trials.
Angiotensin receptor neprilysin inhibitor
The angiotensin receptor neprilysin inhibitor LCZ696, 
combining the two acting agents valsartan and sacubi-
tril, has revolutionized treatment of HFrEF. By inhibi-
tion of neprilysin, sacubitril increases ANP-, BNP- and 
CNP-plasma levels [33]. These peptides can then activate 
guanylyl cyclase resulting in formation of cGMP. Moreo-
ver, natriuretic peptides help to prevent myocardial fibro-
sis and to lower blood pressure due to vasodilation and 
increased diuresis [33]. As discussed above, prognosis 
of patients with HFpEF is affected by comorbidities such 
as diabetes. A post hoc analysis of the PARADIGM-HF 
trial revealed that sacubitril enhances glycemic control 
and reduces the necessity of insulin treatment in HFrEF 
patients [78]. This could be a further beneficial effect in 
patients with HFpEF, where diabetes is thought to trigger 
the disease. The PARAGON-HF trial evaluated therapy 
with LCZ696, and enrolled 4822 patients with HF and 
LVEF ≥ 45% [53]. As recently presented, LCZ696 failed 
to reduce the primary composite endpoint of total hospi-
talizations for HF and CV death. However, prespecified 
subgroup analyses suggested positive effects of LCZ696 
in female patients and those with an LVEF at or below 
the median of all enrolled patients (45–57%). Similarly, 
it was shown that treatment effects of LCZ696 are modi-
fied by LVEF, leading to the greatest benefits in patients 
with an LVEF of < 50% [79]. These findings are in accord-
ance with several post hoc analyses of previous HF trials 
such as TOPCAT [66], CHARM [80], and a meta-analysis 
on beta-blocker effects in HF [81] that have shown posi-
tive treatment effects for patients exhibiting an LVEF of 
40–49%. Of note, these patients have to be categorized as 
HFmEF according to the ESC guidelines [7]. Moreover, 
a recent post hoc analysis of PARAGON-HF documented 
a significant treatment effect of LCZ696 in women, while 
there were no significant effects in men [82]. Furthermore, 
an important limitation of the PARAGON-HF trial con-
sists in the missing exclusion of specific causes such as 
Amyloidosis and M. Fabry which are resistant to treatment 
with LCZ696.
In conclusion, results from the PARAGON-HF trial sup-
port the heterogeneity of the HFpEF syndrome as well as the 
importance of an individually tailored approach in HFpEF 
therapy. In this context, identifying specific causes of HFpEF 
by an aetiological work-up is of great importance. Moreo-
ver, LCZ696 might be associated with beneficial effects in 
female patients and those with a LVEF between 45–57% 
which would include both HFmEF and HFpEF patients. 
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This aspect may underline the limitations of subdividing 
HF phenotypes solely by LVEF. As the primary endpoint of 
PARAGON-HF was neutral, new prospective randomized 
studies in dedicated subgroups might scrutinize efficacy of 
LCZ696 in selected individuals.
Ivabradine
In a mouse model of HFpEF, established by diabetic mice 
(db/db), β-adrenergic receptor-independent reduction of HR 
with ivabradine, an inhibitor of the funny current, improved 
vascular stiffness, as well as systolic and diastolic function 
[83]. However, according to experimental data, this particu-
lar mouse model is not associated with marked structural 
remodeling of the heart [84]. In the EDIFY study, ivabradine 
reduced HR by 30%, but failed to improve E/e′ ratio, exercise 
tolerance, and NT-proBNP levels in HFpEF patients [85]. 
Apparently, the pathophysiological concept of prolonging 
diastole to improve diastolic function and prognosis cannot 
be applied to patients with HFpEF. A plausible explanation 
might be that chronotropic incompetence in HFpEF patients 
contributes to impaired exercise tolerance and ivabradine 
further reduces the exercise-induced increase in HR [86].
Cardiac glycosides
In the DIG trial, cardiac glycosides were able to decrease 
the risk for overall hospitalization and hospitalization 
due to worsening HF in patients with HFrEF and HFpEF 
(LVEF > 45%) [58]. On the contrary, there have been no sig-
nificant differences between digoxin and placebo regarding 
overall and CV mortality [59]. As a result, cardiac glyco-
sides can be considered as a potential treatment to control 
tachyarrhythmia in patients with HFpEF.
New options in treatment of HFpEF
All main approaches regarding device and pharmacological 
therapy in HFpEF patients are highlighted in Fig. 2. Moreo-
ver, all current pharmacological and device trials in HFpEF 
patients are summarized in Tables 1, 2, 3.
Pharmacological
Regulation of  the  NO–cGMP–PKG‑axis Intervention in the 
nitrogen monoxide–cyclic guanosine monophosphate–
protein kinase (NO–cGMP–PKG)-axis represents a new 
promising approach in treatment of HFpEF. Experimental 
data suggest that disturbance of this signal cascade poses a 
specific pathomechanism in HFpEF, which promotes myo-
cardial fibrosis, eventually leading to diastolic dysfunction 
[87, 88]. Therefore, targeting the NO–cGMP–PKG path-
way with phosphodiesterase-5 (PDE5) inhibitors, soluble 
guanylyl cyclase activators/stimulators, angiotensin recep-
tor neprilysin inhibitor as well as NO-inducing drugs such 
as organic nitrates, inorganic nitrites/nitrates, β3 adrenergic 
receptor (β3-AR)-selective agonists, or endothelial nitric 
oxide synthase (eNOS) enhancer have been studied (Fig. 3).
Enhancing NO  bioavailability NO-donating drugs Direct 
NO donators, for instance organic nitrates (isosorbide-
nitrate), are not recommended in HFpEF patients. In the 
multicenter trial Neat-HFpEF on 110 patients with HFpEF, 
isosorbide mononitrate treatment even resulted in decreased 
activity levels [89]. One major disadvantage of organic 
nitrates is a strong vasodilatation, which can reduce sys-
temic blood pressure dramatically. Inorganic nitrites, on the 
other hand, appear to improve ventricular performance with 
stress, especially by reducing pulmonary capillary wedge 
pressure (PCWP) and bear a much lower risk for reduc-
tion of systemic blood pressure [45]. Moreover, inorganic 
nitrites evolve their specific effects on hemodynamics pre-
cisely during exercise, presumably when patients benefit the 
most from symptom relief [90]. These effects also account 
for inorganic nitrates, the precursor to nitrite [91]. How-
ever, in the multicenter RCT INDIE-HFpEF, treatment with 
inhaled inorganic nitrite failed to increase exercise capacity, 
QOL, NYHA functional class, diastolic function (E/e′), and 
NT-proBNP levels [92]. As for now, results of the ongoing 
KNO3CKOUT-HFpEF trial, investigating effects of orally 
active potassium nitrate capsules, should be awaited, as they 
could differ from these previous findings (NCT02840799).
β3AR-selective agonists Conventional beta-blockers 
mainly target β1- and β2-adrenoreceptors (β1-AR/β2-AR), 
which can mediate maladaptive effects of prolonged cat-
echolamine exposure including cardiac remodeling [93]. 
Moreover, a third subtype of β-adrenoreceptors, β3-AR, has 
been identified in human hearts [94]. In contrast to β1-AR 
and β2-AR, these receptors prevent the myocardial hyper-
trophic response to neurohormonal stimulation [95]. As 
a result, the concept of stimulating β3-AR with the selec-
tive agonist mirabegron as a therapeutic option in HFpEF 
is currently studied in two clinical trials (NCT02775539, 
NCT02599480).
Endothelial nitric oxide synthase (eNOS) activators 
Enhancing eNOS activity by the transcription amplifier 
AVE3085 results in increased production of NO and was 
shown to be associated with a significant improvement in 
diastolic function in a rat model [96]. However, clinical 
evaluation of the approach is still pending.
Potential limitations of enhancing NO bioavailability 
According to a recent mouse model, nitrosative stress needs 
to be acknowledged as one of the main drivers in HFpEF 
rather than the limited bioavailability of NO [97]. In this 
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model, concomitant metabolic and hypertensive stress 
resulted in increased activity of inducible nitric oxide syn-
thase (iNOS) which interfered with the inositol-requiring 
protein 1α (IRE1α)—X-box-binding protein 1 (XBP1) 
pathway. These findings could explain why NO-induc-
ing approaches have failed so far and could lead to new 
approaches targeting nitrosative stress, particularly inhibi-
tion of iNOS activity, in the future.
Phosphodiesterase-5 inhibitors Therapy with the PDE5 
inhibitor sildenafil did not improve pVO2 in HFpEF patients 
without evidence of pulmonary hypertension (PH) [98] and 
failed to significantly lower pulmonary artery pressure 
(PAP) and to improve hemodynamic parameters in patients 
suffering from HFpEF and resulting postcapillary PH [99]. 
However, use of sildenafil is an established therapy regimen 
in patients with precapillary PH and may be considered in 
certain forms of combined pre- and postcapillary PH (CpC-
PH) when coexistence of pulmonary arterial hypertension 
(PAH) and left heart disease is most likely. In accordance, 
it was shown that sildenafil can yield positive therapeutic 
effects in patients with HFpEF and severe forms of CpC-PH 
[100]. Translation of these findings into general therapeutic 
recommendations needs to be evaluated in future studies 
(2010-020153-14).
Soluble guanylyl cyclase stimulators and activators 
Vericiguat and riociguat, primarily used to treat PH, have 
been analyzed in HF patients in phase 2 clinical studies. 
As the SOCRATES-PRESERVED trial has shown, veri-
ciguat improved QOL, but failed to reduce NT-proBNP 
levels or left-atrial volumes [101]. Currently, therapy with 
sGC stimulators and activators is further studied in vari-
ous trials (NCT03153111, NCT03254485, NCT02744339, 
and NCT03547583). The RCT VITALITY-HFpEF 
(NCT03547583) for instance, will primarily evaluate treat-
ment effects of vericiguat regarding physical function 
Fig. 2  Main approaches regarding device and pharmacological ther-
apy in HFpEF patients. Renal denervation can lower sympathetic 
activity resulting in decreased neprilysin activation, end-systolic vol-
umes, and cardiac fibrosis as well as increased levels of natriuretic 
peptides. By implantation of an atrial shunt device, left-atrial pres-
sure can be reduced. Continuous measurement of pulmonary artery 
pressure with the CardioMEMS device helps to prevent cardiac 
decompensation. CRT devices target mechanical LV dyssynchrony in 
HFpEF patients. CCM devices aim to enhance myocardial contractil-
ity. Main pharmacological approaches in HFpEF comprise regulation 
of the NO–cGMP–PKG-axis, restoring mitochondrial energy, modu-
lation of intracellular  Ca2+ sensitivity as well as targeting cardiac 
inflammation and fibrosis. Furthermore, inhibition of the sodium glu-
cose cotransporter-2 represents another important approach in HFpEF 
therapy, although the exact pathomechanisms are currently unknown. 
ASD atrial shunt device, CCM cardiac contractility modulation, CRT 
cardiac resynchronization therapy, eNOS endothelial nitric oxide 
synthase, miRNA micro-RNA, MRA mineralocorticoid receptor 
antagonist, NO–cGMP–PKG nitrogen monoxide–cyclic guanosine 
monophosphate–protein kinase, RDN renal denervation. Figure modi-
fied according to Lam et al. [9] and Böhm et al. [135]
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assessed by the KCCQ PLS (Kansas City Cardiomyopathy 
Questionnaire Physical limitation score).
Anti‑diabetic drugs Sodium-glucose cotransporter-2 inhib-
itors After empagliflozin led to a striking reduction of CV 
events in patients with type 2 diabetes at high CV risk in 
the EMPA-REG OUTCOME study [102], treatment with 
SGLT2 inhibitors was evaluated in HF patients with and 
without diabetes. As shown in the recent DAPA-HF trial, 
dapagliflozin resulted in a significant decrease of the pri-
mary composite endpoint of worsening HF or CV death in 
4744 HFrEF patients, regardless of the presence or absence 
of diabetes [103]. Among the various pathomechanisms 
under discussion are the increase in renal function due to 
inhibition of the tubuloglomerular feedback system, the 
reduction in heart load as a result of the decrease in preload 
and afterload, and the improvement in cardiac energetics 
through an increase in ketones’ supply [104, 105]. However, 
it is unknown whether these effects will account for HFpEF 
patients also. Finally, experimental data suggested that 
empagliflozin causes direct pleiotropic effects by improving 
diastolic stiffness, which are independent of diabetic con-
ditions [106]. Currently, two large phase-III RCTs, includ-
ing both HFpEF patients with and without diabetes, will 
investigate effects of the SGLT2 inhibitors empagliflozin 
(EMPEROR-PRESERVED; NCT03057951) and dapagli-
flozin (DELIVER; NCT03619213) on HF hospitalizations 
and CV mortality. In addition, the PRESERVED-HF trial 
with dapagliflozin (NCT03030235) and the EMPERIAL-
PRESERVED trial with empagliflozin (NCT03448406) will 
primarily focus on treatment effects in regard to exercise 
capacity as measured by the 6MWD and NT-pro-BNP lev-
els. According to a recent press release, empagliflozin did 
not have any significant effects on the primary endpoint in 
the EMPERIAL-PRESERVED trial [107].
Incretins Modulation of the incretin system includes 
mimicking glucagon-like peptide 1 (GLP-1) effects and 
inhibition of the GLP-1-degrading enzyme dipeptidyl pepti-
dase-4 (DPP-IV) [108]. GLP-1, one of the major incretins, 
is released after food intake and stimulates insulin secretion 
from pancreatic β-cells [108]. The corresponding GLP-1 
receptors are also found in cardiac myocytes and in certain 
regions of the brain [109]. In large cohorts of patients with 
type 2 diabetes at high CV risk, semaglutide and liraglu-
tide, both GLP-1 mimetics, were able to significantly reduce 
mortality [110, 111]. Currently, there is only one small trial 
in HFpEF patients, which investigates effects of sitagliptin 
on hemodynamics as well as diastolic dysfunction and LV 
hypertrophy (NCT-2012–002,877-71).
Targeting cardiac fibrosis and  inflammation Pirfenidone 
represents an anti-fibrotic drug which targets the TGF-β 
signaling pathway and is mainly used in idiopathic pulmo-
nary fibrosis [112]. By activation of myofibroblasts, TGF-β 
can promote the production of fibronectin, proteoglycans and 
type I–III collagen. In mouse models with pressure-overload 
induced HF, pirfenidone inhibits progression of contractile 
dysfunction and LV fibrosis after beginning of treatment 
[113]. The PIROUETTE-trial will investigate whether these 
effects account for HFpEF patients also (NCT02932566).
Cross-link breakers Cross-link breakers target advanced 
glycation endproducts (AGEs), which are formed by pro-
teins and carbohydrates that underwent “cross-linking” 
with the extracellular matrix [114]. Production of AGEs 
Table 1  Current pharmacological and device trials in HFpEF patients focusing on clinical outcomes
CV cardiovascular, HF heart failure, IV intravenous, KCCQ Kansas City Cardiomyopathy Questionnaire, QOL quality of life
Study name Intervention Study size Primary endpoint Identifier
Sodium glucose cotransporter-2 inhibitors
EMPEROR-PRESERVED Empagliflozin 4126 Change in CV death rate, time-to-first HF hospitalization NCT03057951
DELIVER Dapagliflozin 4700 Change in CV death rate, time-to-first HF hospitalization/first 
urgent HF visit
NCT03619213
SOLOIST Sotagliflozin 4000 Change in CV death rate, time-to-first HF hospitalization NCT03521934
Mineralocorticoid receptor antagonists
SPIRRIT Spironolactone 3500 Change in overall death rate NCT02901184




GUIDE-HF CardioMEMS 3600 Change in all-cause mortality, total number of HF hospitaliza-
tions, iv diuretic visits
NCT03387813
REDUCE LAP-HF TRIAL II IASD System II 608 Change in incidence of and time-to-CV mortality or first non-
fatal, ischemic stroke, total rate per patient year of HF admis-
sions or healthcare facility visits for IV diuresis for HF and 
time-to-first HF event, KCCQ
NCT03088033
1088 Clinical Research in Cardiology (2020) 109:1079–1098
1 3
is triggered by oxidative stress and is associated with 
impaired diastolic function [115]. In a small cohort of 23 
patients, treatment with the cross-link breaker Alagebrium 
chloride decreased LV mass and improved LV diastolic 
filling and QOL [116]. A similar concept which aims to 
interfere with the formation of AGEs is the antibody-
mediated inhibition of the enzyme Lysyl oxidase-like 2 
(Loxl2). Loxl2 can contribute to the cross-linking of colla-
gen, eventually leading to interstitial fibrosis and diastolic 
dysfunction [115]. In mouse models, inhibition of Loxl2 
improved systolic and diastolic function [117]. Clinical 
evaluations of Loxl2-inhibition and new cross-linking 
strategies have to be awaited.
Micro-RNAs Micro-RNAs (miRNAs) are small non-cod-
ing RNA molecules which can interfere with gene expres-
sion on a post-transcriptional level by binding to messenger-
RNA [118]. There is a variety of different miRNAs, and 
their profiles typically differ between patients with HFpEF 
and HFrEF [119, 120]. For instance, inhibition of miRNA-
21 prevented development of HFpEF, which was associated 
with reduced expression of the anti-apoptotic gene Bcl-2 
in rats [121]. Therefore, targeting miRNAs and trying to 
interfere with their effects might introduce a new potential 
therapy regimen in the future. However, the knowledge 
about the mechanisms of action is incompletely resolved 
and needs to be understood better before these concepts will 
be tested in clinical trials.
Cytokine inhibitors Derived from the pathophysiologi-
cal model of systemic inflammation being one of the main 
mediators in the development of HFpEF, cytokine inhibitors 
have been tested as therapeutic options. In the D-HART2 
trial [122], interleukin-1 (IL-1) blockade with anakinra was 
not able to improve aerobic exercise capacity in terms of 
VO2 and ventilatory efficiency. However, in a sub-analysis 
of the large RCT CANTOS [123] including patients with 
previous myocardial infarction, increased high-sensitivity 
C-reactive protein levels and history of HF, therapy with 
canakinumab, a monoclonal antibody targeting IL-1ß, sig-
nificantly decreased risk of HF hospitalizations as well as 
the composite of HF hospitalization or HF-related mortality 
[124].
Cell therapy Cell therapy targets myocardial inflamma-
tion and myocardial fibrosis in HFpEF. In rat models, appli-
cation of cardiosphere-derived cells (CDCs) decreased LV 
fibrosis and inflammatory infiltrates achieving normalization 
of LV relaxation and diastolic pressures and, therefore, led 
to an improvement in survival [125]. The safety of this con-
cept will be studied in the ongoing REGRESS-HFpEF-trial 
(NCT02941705). Furthermore, a pilot study on 14 patients 
with HFpEF showed that treatment with  CD34+ cells, col-
lected by apheresis after G-CSF stimulation, resulted in an 
enhancement in diastolic function (E/e′), and decreased NT-
proBNP levels [126].  CD34+ cell therapy in patients with 
HFpEF is currently under further evaluation in the CELL-
pEF-trial (NCT02923609). However, cell therapy has been 
evaluated as a promising therapy for CV diseases in numer-
ous past trials without delivering consistent and convincing 
results. Questions about optimal cell type, dose, and delivery 
route are still inadequately answered [127].
Restoring mitochondrial energy Szeto-Schiller peptides 
“Szeto-Schiller peptides (SS peptides)” belong to a new 
Table 2  Current pharmacological and device trials in HFpEF patients focusing on biomarker levels, quality of life, and cognitive function
QOL quality of life, NT-pro-BNP N-terminal-pro hormone B-type natriuretic peptide
Study name Intervention Study size Primary endpoint Identifier
Soluble guanylyl cyclase stimulators and activators
SERENADE Macitentan 300 Change in NT-proBNP levels NCT03153111
VITALITY Vericiguat 735 Change in QOL NCT03547583
Inorganic nitrates/nitrites
PMED Oral nitrate 120 Change in nitrate/nitrite level, microbiome NCT02980068
Angiotensin receptor neprilysin inhibitor
PERSPECTIVE LCZ696 520 Change in cognitive function NCT02884206
PARALLAX LCZ696 2500 Change in NT-proBNP levels NCT03066804
Sodium glucose cotransporter-2 inhibitors
PRESERVED-HF Dapagliflozin 320 Change in NT-proBNP levels NCT03030235
ERADICATE-HF Ertugliflozin 36 Change in proximal sodium reabsorption NCT03416270
Restoring mitochondrial energy
Elamipretide in patients hospitalized 
with congestion due to HF
Elamipretide 300 Change in NT-pro-BNP levels NCT02914665
Device therapy
CCM-HFpEF CCM 50 Change in QOL NCT03240237
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class of antioxidant peptides that bind to the cardiolipin, an 
important phospholipid in the inner mitochondrial mem-
brane. SS peptides protect cardiolipin from oxidation and, 
thereby, prevent the damage of oxidative stress to mitochon-
dria, maintaining ATP production and reducing further oxi-
dative stress [128]. The most prominent and first compound 
is elamipretide (MTP-131, SS31) which has been subject of 
clinical studies after experimental data delivered encourag-
ing results [129]. In the EMBRACE-STEMI study, elami-
pretide was safe, but failed to reduce infarct size as assessed 
by CK-MB levels in patients during/after ST-elevation myo-
cardial infarction and successful percutaneous coronary 
intervention [130]. In patients with HFpEF, elamipretide 
reduced left-ventricular end-diastolic volumes compared to 
placebo after 4  h of infusion [131]. Currently, two phase 
II clinical trials test the clinical efficacy of elamipretide 
Table 3  Current pharmacological and device trials in HFpEF patients focusing on echo/hemodynamic parameters
CO cardiac output, ECV extracellular volume fraction, LVMI left-ventricular mass index, PAP pulmonary arterial pressure, PCWP pulmonary 
capillary wedge pressure, PVR pulmonary vascular resistance, QOL quality of life, RVSP right-ventricular systolic pressure, SVR systemic vascu-
lar resistance, VAT ventilatory anaerobic threshold, VO2 oxygen consumption
Study name Intervention Study size Primary endpoint Identifier
Soluble guanylyl cyclase stimulators and activators
CAPACITY-HF IW 1973 184 Change in peak VO2 NCT03254485
DYNAMIC Riociguat 114 Change in CO NCT02744339
Phosphodiesterase-5 inhibitors
Sildenafil in HFPEF and PH Sildenafil 52 Change in PAP, CO 2010-020153-14
Inorganic nitrates/nitrites
INABLE Oral inorganic nitrite 100 Change in peak VO2 NCT0271312
KNO3CK OUT HFPEF Oral potassium nitrate 76 Change in QOL, muscle blood flow, SVR reserve NCT0284079
PH-HFPEF Oral nitrite 26 Change in PAP at exercise NCT03015402
ONOH Oral nitrite 18 Change in peak VO2 NCT02918552
Neo40 Oral nitrate supplement 25 Change in exercise capacity, E/e′, RVSP NCT03289481
3AR-selective agonists
BETA3_LVH Mirabegron 297 Change in LVMI, E/e′ NCT02599480
SPHERE-HF Mirabegron 80 Change in PVR NCT02775539
Sodium glucose cotransporter-2 inhibitors
EMPERIAL-PRESERVED Empagliflozin 300 Change in 6MWD NCT03448406
Other antidiabetic drugs
Metformin for PH + HFPEF Metformin 32 Change in PAP at exercise NCT03629340
cGETS Sitagliptin 25 Change in hemodynamics during Dobutamine 
stress test, diastolic dysfunction, LV hypertrophy
2012-002877-71
Pirfenidone
PIROUETTE Pirfenidone 200 Change in ECV NCT02932566
Cell therapy
CELL-pEF CD34+ cell therapy 30 Change in E/e′ NCT02923609
Restoring mitochondrial energy
Elamipretide in subjects with 
stable HFpEF
Elamipretide 46 Change in E/e′ NCT02814097
FAIR-HFpEF Ferric carboxymaltose 200 Change 
in 6MWD
NCT03074591
PREFER-HF Ferric carboxymaltose 72 Change in 6MWD NCT03833336
Targeting intracellular Ca2+ sensitivity
HELP Levosimendan 36 Change in PCWP at exercise NCT03541603
Prostaglandin derivatives
ILO-HOPE Iloprost 34 Change in PCWP after exercise NCT03620526
SOUTHPAW Treprostinil 310 Change in 6MWD NCT03037580
Device therapy
RAPID-HF CRT 30 Change in VO2 at VAT NCT02145351
PREFECTUS CRT 10 Change in systolic and diastolic reserve index NCT03338374
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in patients with acute or chronic HFpEF (NCT02814097, 
NCT02914665).
Adenosine A1 receptor agonists The partial adenosine A1 
receptor agonist Neladenoson bialanate is thought to yield 
several beneficial effects in the heart and also in the skeletal 
muscle. These compromise improvement in mitochondrial 
function and energy substrate utilization, enhanced SER-
CA2a activity, reversion of ventricular remodeling, and pro-
viding anti-ischemic properties [132]. In the PANACHE-
trial (NCT03098979), treatment with Neladenoson bialanate 
failed to significantly affect the primary endpoint “change in 
6MWD” in HFpEF patients [133].
Targeting intracellular calcium homoeostasis and  calcium 
sensitivity Levosimendan According to ESC guidelines, 
levosimendan, a calcium sensitizer and PDE3 inhibitor with 
vasodilative properties [104], can be considered in patients 
with acute HF and severe reduction of cardiac output (CO), 
resulting in compromised vital organ perfusion [7]. The pos-
itive inotropic effect of levosimendan is the result of a com-
bined effect on troponin C (sensitization to calcium binding) 
and PDE3-inhibition, increasing cAMP and calcium [104]. 
Moreover, infusions of levosimendan decreased PAP, NT-
proBNP levels, and inflammatory status by altering the ratio 
of interleukin-6 to interleukin-10 as well as improved dias-
tolic function and right-ventricular systolic function in 54 
patients with advanced HF due to left heart failure (NYHA 
III–IV, LVEF < 35%) [134]. Thus, the current RCT HELP 
will investigate the effects of levosimendan in 36 HFpEF 
Fig. 3  Current pharmacological approaches regarding regulation of 
the NO–cGMP–PGK-axis. Drugs targeting the NO–cGMP–PGK-
axis aim to promote formation of cGMP, which increases PKG activ-
ity. PKG plays a pivotal role in titin phosphorylation contributing to 
reduction in cardiomyocyte passive stiffness [136]. PKG phospho-
rylation targets can also lower levels of key transcription factors and 
sarcomeric proteins mediating LV hypertrophy, diastolic relaxation, 
LV stiffness, and vasorelaxation. Furthermore, PKG-dependent phos-
phorylation of phospholamban can improve sarcoplasmic reticulum 
 Ca2+-ATPase (SERCA) activity [137] and, therefore, helps to prevent 
 Ca2+ mishandling. PDE5 inhibitors (I) protect cGMP from degrada-
tion by PDE5. While sGC activators (II) bind to nonoxidized sGC 
 (Fe2+), sGC stimulators (III) target oxidized sGC  (Fe3+). Neprilysin 
inhibitors (V) prevent degradation of natriuretic peptides, particu-
larly ANP and BNP, which can then bind to pGC. NO-donating drugs 
(IV) enhance bioavailability of NO, leading to stimulation of sGC. 
By binding to β3-AR on endothelial cells, β3-AR-selective agonists 
(VI) promote activity of eNOS, resulting in production of NO. The 
eNOS enhancer AVE3085 (VII) directly affects eNOS. ANP atrial 
natriuretic peptide, β3-AR β3 adrenergic receptor, BH2 dihydrobi-
opterin, BH4 tetrahydrobiopterin, BNP B-type natriuretic peptide, 
DHFR dihydrofolate reductase, DPP4 dipeptidyl peptidase-4, eNOS 
endothelial nitric oxide synthase, GTP guanosine triphosphate, PDE 
phosphodiesterase, pGC particulate guanylate cyclase, PKG pro-
tein kinase G, ROS reactive oxygen species, sGC soluble guanylate 
cyclase. Figure modified according to Papp et  al. [138] and Kovacs 
et al. [139]
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patients with diagnosed group 2 PH (PH due to left heart 
disease) (NCT03541603).
Prostacyclin analogues In patients with group 2 PH and 
HFpEF, administration of inhaled iloprost led to an acute 
reduction of PAP and pulmonary vascular resistance (PVR) 
during right heart catheterization [135]. The two RCTs ILO-
HOPE and SOUTHPAW will help to further evaluate treat-
ment effects of prostacyclin analogues in patients suffering 
from HFpEF (NCT03037580, NCT03620526).
Device therapies
Home monitoring Fluid overload in patients with HFpEF 
can rapidly reduce QOL by causing dyspnea and periph-
eral edema or even lead to hospitalization due to cardiac 
decompensation. Since hospitalization for HF is associ-
ated with a higher mortality risk [136], monitoring of HF 
patients to avoid symptom deterioration or hospitalization 
has come into focus as one important part of the therapy. In 
2007, the first studies introduced monitoring of HF patients 
with a new radiofrequency-based wireless pressure sen-
sor (CardioMEMS device), implanted into the pulmonary 
artery and which continuously monitors pulmonary artery 
pressure [137, 138]. In the subsequent CHAMPION trial, 
usage of CardioMEMS in NYHA III patients with HFpEF 
and HFrEF was able to reduce HF-related hospitalizations 
[139]. The 1  year outcome results of the CardioMEMS 
Postapproval study confirmed efficacy of home monitoring 
in 1200 HF patients [140]. After implantation of the Cardi-
oMEMS device, event rate of HF hospitalization/all-cause 
death per patient year was reduced by 44%. The large multi-
center RCT GUIDE-HF will try to reproduce these results in 
3600 symptomatic HF patients (NCT03387813).
Atrial shunt device The idea of creating artificial left–right 
shunts to reduce left-atrial pressure originates from a pub-
lication from the early twentieth century. The so-called 
Lutembacher syndrome was used to describe the finding 
that patients with an untreated mitral stenosis and resulting 
increase in left-atrial pressure benefit from a concomitant 
atrial septal defect [141]. In a pilot trial, which included 11 
patients with an LVEF of at least 45%, implantation of an 
atrial shunt device led to a significant reduction of LV-filling 
pressures after 30 days [142]. Remarkably, no patient devel-
oped PH after the procedure. Analogously, the REDUCE 
LAP-HF I trial on a total of 64 patients recorded a reduction 
in left-atrial pressure during exercise with improvement in 
functional capacity and QOL after shunt implantation [143]. 
The latest 1-year results of REDUCE LAP-HF I showed no 
significant differences in major adverse cardiac, cerebrovas-
cular, or renal events compared to patients who underwent 
sham procedure, suggesting this method to be safe [144]. In 
the future, the REDUCE-LAP-HF II trial, which focuses on 
clinical outcomes, will hopefully take up from these positive 
results (NCT03088033).
Cardiac resynchronization therapy (CRT) In HFpEF 
patients, LV mechanical dyssynchrony has been suggested 
to contribute to an impairment of longitudinal systolic and 
diastolic LV function and to be associated with higher 
LV-filling pressures and worse clinical status in terms of 
NYHA functional class [145]. On the other hand, a post 
hoc analysis of the TOPCAT trial has shown that LV 
mechanical dyssynchrony is not associated with outcomes 
of HFpEF patients [146]. Targeting LV dyssynchrony by 
implantation of a CRT device is currently subject of ongo-
ing studies, which will help to better understand its rel-
evance for the therapy of HFpEF patients (NCT03338374, 
NCT02145351).
Cardiac contractility modulation (CCM) CCM aims to trig-
ger molecular remodeling by delivering electrical signals 
into the septum during the refractory period and has been 
associated with numerous beneficial effects in chronic HF 
such as increased titin and troponin phosphorylation, and 
reduced expression of proteins that mark cardiac fibrosis 
[147]. In two female patients, CCM has been shown to 
improve clinical status and echocardiographic parameters 
early after initiation of CCM therapy [148]. The CCM-
HFpEF trial will study the effects of CCM on QOL in 
patients with HFpEF (NCT03240237).
Renal denervation Renal denervation (RDN), a catheter-
based, radiofrequency ablation of the renal sympathetic 
nerves, has been shown to effectively lower both systolic 
and diastolic blood pressure [149, 150]. Furthermore, 
reduction of cardiac sympathetic activity occurs inde-
pendently from blood pressure reduction, suggesting 
direct effects on the heart [151]. As a consequence, RDN 
reduced LV mass and improved diastolic function [152–
154]. However, the underpowered RDT-PEF trial includ-
ing 25 patients with HFpEF did not confirm a beneficial 
effect of RDN on diastolic parameters and QOL [155]. 
Further investigations are needed to clarify the therapeutic 
value of RDN in HFpEF.
What is left?
Fluid overload can cause preload increase and as a result 
cardiac decompensation. Patients may suffer from periph-
eral edema and signs of congestion such as dyspnea. There-
fore, diuretics, which are established drugs to treat fluid 
overload and signs of congestion, are a cornerstone in the 
symptomatic therapy of HFpEF [7]. Treatment with ACE 
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inhibitors or ARBs did not result in further improvement 
regarding QOL, exercise capacity, or myocardial function 
after initiation of optimal diuretic therapy [156]. However, 
overtreatment should be avoided as it can cause excessive 
preload reduction and reduction in filling pressures, which 
stiff hearts may depend on [33].
Summary and perspective
The 2016 ESC/HFA guidelines [7] acknowledge the fact 
that no treatment has been convincingly shown to reduce 
morbidity or mortality in HFpEF patients. Since then, fur-
ther efforts have been made to improve understanding and 
treatment of the HFpEF syndrome. However, diagnosis of 
HFpEF remains controversial and there is growing apprecia-
tion that HF, and particular HFpEF, represents a heterogene-
ous syndrome with various phenotypes and comorbidities 
which are hardly to differentiate solely by LVEF and might 
benefit from individually tailored approaches [9, 157]. These 
aspects are also supported by the results of the recently pre-
sented PARAGON-HF trial [53], which failed to show ben-
eficial treatment effects of LCZ696 in HFpEF patients, but 
has been associated with positive effects in female patients 
and patients with an LVEF between 45–57%. In the future, 
prospective randomized studies should be conducted in well-
defined, dedicated subgroups which take various informa-
tion (clinical characteristics, biomarker levels, and imaging 
modalities) into account. In this context, new diagnostic 
techniques such as novel imaging strategies may help to dif-
ferentiate the etiologies of HFpEF, to identify situations with 
specific treatment options, and to stratify available treat-
ments. Among the various therapeutic approaches that have 
been introduced lately, therapy with SGLT2 inhibitors prom-
ises the greatest potential for the future, as it has just been 
proven efficient in HFrEF patients and is currently studied 
in two large RCT. In addition, innovative device therapies, 
in particular creating artificial left–right shunts by implanta-
tion of an atrial shunt device, pose exciting options for the 
future, but need to be proven safe first. As for now, treatment 
of HFpEF is limited to symptom relief, which effectively 
improves QOL. Therefore, further research is desperately 
needed, to manage the challenging syndrome HFpEF.
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